Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Multi-cohort, Prospective Phase II Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma

NCT07355855 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07355855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07355855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Multi-cohort, Prospective Phase II Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 31, 2026
Completion date
January 31, 2029
Enrollment
106 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rhabdomyosarcoma